Halozyme Therapeutics (HALO) 資深副總裁 Michael J. Labarre 出售 10,000 股股票

Halozyme Therapeutics, Inc.（納斯達克股票代碼：HALO – 獲取免費報告）高級副總裁 Michael J. Labarre 在 7 月 24 日星期三的一次交易中出售了 10,000 股該公司股票。

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $55.12, for a total value of $551,200.00. Following the completion of the transaction, the senior vice president now directly owns 168,176 shares in the company, valued at approximately $9,269,861.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Halozyme Therapeutics, Inc.（納斯達克股票代碼：HALO）高級副總裁 Michael J. Labarre 在 7 月 24 日星期三的一次交易中出售了 10,000 股該公司股票。這些股票的平均售價為 55.12 美元，總價值為 551,200.00 美元。交易完成後，高級副總裁現直接擁有公司168,176股，價值約9,269,861.12美元。該交易已在向美國證券交易委員會提交的文件中披露，可透過此超連結存取該文件。

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics 股票表現

Shares of HALO opened at $55.15 on Thursday. The company has a 50-day simple moving average of $49.62 and a two-hundred day simple moving average of $42.35. Halozyme Therapeutics, Inc. has a one year low of $32.83 and a one year high of $56.50. The firm has a market capitalization of $7.02 billion, a PE ratio of 22.79, a price-to-earnings-growth ratio of 0.56 and a beta of 1.27. The company has a debt-to-equity ratio of 8.44, a current ratio of 6.64 and a quick ratio of 5.36.

HALO 股價週四開盤價為 55.15 美元。該公司的 50 天簡單移動平均線為 49.62 美元，200 天簡單移動平均線為 42.35 美元。 Halozyme Therapeutics, Inc. 的一年最低價為 32.83 美元，一年最高價為 56.50 美元。該公司市值為70.2億美元，市盈率為22.79，市淨增長率為0.56，貝塔值為1.27。該公司的負債股本比率為8.44，流動比率為6.64，速動比率為5.36。

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.07. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. The firm had revenue of $195.88 million during the quarter, compared to analyst estimates of $201.72 million. On average, analysts anticipate that Halozyme Therapeutics, Inc. will post 3.66 EPS for the current fiscal year.

Halozyme Therapeutics（納斯達克股票代碼：HALO）最近於 5 月 7 日星期二發布了財報。該生物製藥公司本季每股盈餘 (EPS) 為 0.71 美元，比市場普遍預期的 0.64 美元高出 0.07 美元。 Halozyme Therapeutics 的淨利潤率為 36.94%，股本回報率為 225.71%。該公司本季營收為 1.9588 億美元，而分析師預計為 2.0172 億美元。分析師平均預期 Halozyme Therapeutics, Inc. 本會計年度的每股收益將為 3.66。

Wall Street Analysts Forecast Growth

華爾街分析師預測成長

Read Our Latest Report on Halozyme Therapeutics

閱讀我們關於 Halozyme 療法的最新報告